Gilead to acquire cell therapy partner Arcellx for $7.8B
Gilead to acquire cell therapy partner Arcellx for $7.8B
Contenu indisponible. Consultez la source originale.
Gilead to acquire cell therapy partner Arcellx for $7.8B
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.